Mi az ára Provention Bio, Inc. (PRVB)

Provention Bio, Inc. (PRVB) ára $24.98

Mi a Provention Bio, Inc. (PRVB piaci tőkésítése)

Provention Bio, Inc. piaci tőkésítése (PRVB) $1.01B

Provention Bio, Inc. (PRVB) Árfolyamtörténet

Provention Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and bringing to market therapies aimed at intercepting and preventing autoimmune disorders. Their lead investigational candidate, PRV-031 (teplizumab, a monoclonal antibody), is currently in a Phase III clinical trial for the interception of Type 1 Diabetes (T1D). Another asset, PRV-3279, has successfully completed its Phase Ib clinical trial for the treatment of lupus. The company is also developing PRV-101, a vaccine targeting coxsackie virus B (CVB) to prevent both acute CVB infections and the onset of T1D. Additionally, PRV-015 is undergoing a Phase IIb clinical trial, offering a potential treatment for celiac disease that does not respond to a gluten-free diet. Provention Bio has established strategic partnerships to advance its pipeline. This includes a licensing and collaboration agreement with Amgen Inc. for PRV-015, described as a novel anti-IL-15 monoclonal antibody, for the continued development against gluten-free diet non-responsive celiac disease. Furthermore, a strategic alliance with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. focuses on the development and commercialization of PRV-3279 in Greater China. PRV-3279 is characterized as a bispecific antibody-based molecule designed to target B cell surface proteins CD32B and CD79B. Founded in 2016, Provention Bio, Inc. maintains its headquarters in Red Bank, New Jersey.

Év	Teljesítmény
2023	158.40%
2022	53.04%
2021	-64.36%
2020	44.04%
2019	443.29%
2018	0.00%

Év

Teljesítmény

2023

158.40%

2022

53.04%

2021

-64.36%

2020

44.04%

2019

443.29%

2018

0.00%

Vállalat	Részvényár	Változás 1év%	Ország
Vertex Pharmaceuticals Incorporated VRTX.US	$542.09	38.63%	US
Argenx SE ARGX.US	$1.03K	44.13%	NL
CSL Limited CSL.AX	$121.53	-12.70%	AU
Moderna, Inc. MRNA.US	$138.18	473.58%	US
Lonza Group AG LONN.SW	$759.27	7.20%	CH

Vállalat

Részvényár

Változás 1év%

Ország